Latest News and Press Releases

Washington, D.C., June 11, 2025 (GLOBE NEWSWIRE) -- On the second Thursday in June, Global Fatty Liver Day (formerly International NASH Day) spotlights one of the most widespread yet under-addressed...

Third asset to advance into clinical trials, validating broad potential of Launch-iT platformAll subjects treated with first dose of AVX70371 Launch-iT, as part of multiple dosing schedule Potential...

Chiffre d'affaires de 9,2 millions d'euros pour l’année 2024Trésorerie et équivalents de trésorerie à 96,6 millions d’euros au 31 décembre 2024Levée d’un produit brut de 116 millions d’euros dans le...

Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million Structured Financing closed with aggregate...

Les résultats seront présentés lundi 18 novembre par poster lors de la session « late-breaker » du congrès de l’AASLD The Liver Meeting® à San Diego.L'étude LEGEND a atteint son critère principal...

Data will be presented on Monday, November 18th as a late breaker poster at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 in San Diego.LEGEND achieved its...

Washington, DC, Sept. 03, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Global Liver Institute (GLI), the premier liver patient advocacy organization, has appointed Larry R. Holden as the...

Chemomab reported positive topline results from Ph 2 trial assessing CM-101 in PSC. Achieved safety endpoint and improved wide range of secondary endpoints

Washington, DC, March 14, 2024 (GLOBE NEWSWIRE) -- Today, Global Liver Institute (GLI) recognizes the importance of the first approval by the U.S. Food and Drug Administration (FDA) of a medication...

• Travere received $210 million at closing and is eligible for up to $235 million in potential sales-based milestone payments• Mirum has acquired Travere’s rights and assets related to Cholbam® and...